14 completed, 2 terminated, 1 unknown. 6 Phase 2, 6 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow HRA Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Metyrapone in Patients With Hypercortisolism Metyrapone Capsules - Hypercortisolism | Completed | Istituto Auxologico Italiano | 20 | 2022-04-28 | 2026-03-30 | |
| Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Norgestrel 0.075 mg tablets - Contraception | Phase 3 | Completed | HRA Pharma | 962 | 2019-09-06 | 2022-05-20 |
| Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole. Cushing Syndrome | Unknown | HRA Pharma | 200 | 2018-12-20 | 2022-08-30 | |
| Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill Norgestrel 0.075 mg - Contraception | Phase 2 | Completed | HRA Pharma | 52 | 2018-07-24 | 2021-06-03 |
| A Study of Oral Contraception Under Simulated OTC Conditions Norgestrel 0.075 mg tablets - Contraception | Phase 3 | Terminated | HRA Pharma | 189 | 2018-04-27 | 2022-04-04 |
| A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions Use Phase (Ulipristal Acetate, 30 mg) - Emergency Contraception | Phase 3 | Completed | HRA Pharma | 1270 | 2017-05-23 | 2022-12-02 |
| Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome metyrapone - Cushing's Syndrome | Phase 3 | Completed | HRA Pharma | 50 | 2015-04-01 | 2020-09-25 |
| Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella ella - Emergency Contraception | Completed | HRA Pharma | 98 | 2014-11-18 | 2019-10-21 | |
| Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo. Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon), placebo + ethinylestradiol/levonorgestrel - Emergency Contraception | Phase 4 | Completed | HRA Pharma | 76 | 2012-03-01 | 2013-06-13 |
| Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women ellaOne® (ulipristal acetate) - Contraception | Completed | HRA Pharma | 579 | 2010-05-01 | 2013-05-15 | |
| Glucocorticoid Receptor Antagonism in Subclinical Cushings Mifepristone - Subclinical Cushing's | Phase 1 / Phase 2 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 6 | 2008-11-01 | 2021-01-26 |
| Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge CDB-2914 (ulipristal acetate), Placebo - Contraception | Phase 2 | Completed | HRA Pharma | 35 | 2008-05-01 | 2010-08-25 |
| Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Mifepristone - Cushing's Syndrome | Phase 2 | Terminated | HRA Pharma | 18 | 2007-05-15 | 2019-10-11 |
| Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception CDB-2914, Levonorgestrel - Contraception | Phase 3 | Completed | HRA Pharma | 2221 | 2007-04-01 | 2022-05-03 |
| Safety and Efficacy of CDB-2914 for Emergency Contraception CDB-2914 - Emergency Contraception | Phase 3 | Completed | HRA Pharma | 1623 | 2006-11-01 | 2021-09-21 |
| Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo - Leiomyoma | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 72 | 2006-02-01 | 2024-07-15 |
| Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914 VA2914 - Contraception, Gynecologic Diseases | Phase 2 | Completed | HRA Pharma | 48 | 2004-01-01 | 2010-06-17 |
Cushing Syndrome (4) · ACTH Syndrome, Ectopic (1) · Genital Diseases, Female (1) · Leiomyoma (1)
ulipristal acetate (6) · ulipristal (5) · Norgestrel (3) · Levonorgestrel (2) · Metyrapone (2) · Mifepristone (2) · Ethinyl Estradiol (1) · ethinyl estradiol, levonorgestrel drug combination (1)
United States (10) · United Kingdom (4) · France (3) · Italy (3) · Sweden (3) · Belgium (2) · Germany (2) · Netherlands (2) · Spain (2) · Chile (1) · Croatia (1) · Dominican Republic (1) · Hungary (1) · Ireland (1) · Poland (1)
Paul Fine, MD (2) · Alison Edelman, MD (1) · Anna F Glasier, MD (1) · Chiodini Chiodini, Professor (1) · Dr John Newell Price (1) · Lynnette K Nieman, M.D. (1) · Lynnette K Nieman, MD (1) · Mitchell Creinin, MD (1) · Philippe Bouchard, MD (1) · Russ Bradford, MD, MSPH (1) · Russel Bradford, MD, MSPH (1) · Russell Bradford, MD, MSPH (1) · Sharon Cameron, MD (1)
PMID 17579200, PMID 18448745, PMID 20093897, PMID 20116841, PMID 20634186, PMID 23577182, PMID 25994664, PMID 30239831, PMID 30871768, PMID 32033718, PMID 33970869
1ZIAHD000637-17 (1), 2009 (1)